Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600013 | 0.92 | SIGMAR1 (0.44) | SIGMAR1DRD4MAPTPKMMAPK1 | |
| SCHEMBL3599541 | 0.91 | MAPK1 (0.47) | SIGMAR1DRD4MAPTPKMMAPK1 | |
| SCHEMBL3590840 | 0.90 | ACHE (0.40) | SIGMAR1MAPTPKMMAPK1RAB9A | |
| SCHEMBL3586986 | 0.89 | KDM4E (0.43) | SIGMAR1MAPTPKMMAPK1RAB9A | |
| SCHEMBL3602621 | 0.89 | ACHE (0.39) | SIGMAR1MAPTPKMMAPK1RAB9A | |
| SCHEMBL13254030 | 0.89 | ACHE (0.41) | SIGMAR1MAPTPKMMAPK1RAB9A | |
| SCHEMBL3604419 | 0.88 | ALDH1A1 (0.41) | SIGMAR1MAPTPKMMAPK1RAB9A | |
| SCHEMBL3600324 | 0.88 | TRPV6 (0.42) | SIGMAR1MAPTPKMMAPK1RAB9A | |
| Hydrochloric Acid SCHEMBL3589977 | 0.88 | ACHE (0.40) | SIGMAR1MAPTPKMMAPK1RAB9A | |
| SCHEMBL3602162 | 0.88 | ACHE (0.42) | MAPTPKMMAPK1RAB9ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | SIGMAR1 588/4885DRD4 1983/4885MAPT 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.